-
-
-
-
-
-
-
Goldman Sachs Starts Entrada Therapeutics (TRDA) at Early-Stage Biotech
-
-
-
-
-
-
-
Entrada Therapeutics, Inc. (TRDA) Tops Q1 EPS by 31c
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Entrada Therapeutics (TRDA)
-
-
-
-
-
-
-
Entrada Therapeutics (TRDA) PT Raised to $20 at H.C. Wainwright
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Entrada Therapeutics (TRDA)
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

